We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
People hospitalised following suspected use of unlicensed botulinum toxin products.
An updated joint Enforcement Notice provides important clarity on the kinds of claims and images in an ad that are likely to break the rules.
New National Commission unites clinical leaders, patient advocates and leading tech firms to make the NHS the most AI-enabled healthcare system in world
New Moderna Innovation and Technology Centre opened as government further boosts life sciences sector with £50 million fund.
Paracetamol should be taken as directed in the patient information leaflet
The importance of medicine safety and how to report side effects of medicines via the Yellow Card scheme is now part of the statutory guidance for schools in England.
As part of developing its new five-year strategy, the MHRA is publishing a series of blogs on the challenges and opportunities ahead. In the first instalment, Chief Executive Lawrence Tallon reflects on the changing healthca…
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 16th September 2025, approved the medicine vorasidenib (Voranigo).…
Patients implanted with affected devices should expect to be contacted directly for a follow-up assessment, if required.
As with any medicine, the MHRA will keep the safety of gepotidacin under close review.
As with any medicine, the MHRA will keep the safety of zuranolone under close review.
The pilot will help sponsors prepare for a new substantial modifications process under upcoming regulations, with responses delivered within 14 days.
Parents and caregivers who have purchased Nutrition Ignition Kids Magnesium Glycinate Gummies should stop giving them to children and safely dispose of any remaining product. It is recommended that advice be sought from a he…
As with any medicine, the MHRA will keep the safety and effectiveness of teplizumab under close review.
Letter from the Advisory Council on the Misuse of Drugs (ACMD) to the Minister for Policing and Crime Prevention, about zuranolone.
Letter from the Advisory Council on the Misuse of Drugs (ACMD) to the Minister for Policing and Crime Prevention, about 3 growth hormone agonists.
Letter from the Advisory Council on the Misuse of Drugs (ACMD) to the Minister for Policing and Crime Prevention, about the consideration of ganaxolone.
WHO recognition affirms MHRA’s commitment to regulatory excellence, innovation and global collaboration
The microscopic bacteria living in women’s bodies could be a powerful tool for personalised, non-invasive treatment and earlier diagnosis.
Under a joint information sharing agreement, pharmaceutical companies will be invited to register early with the MHRA and NICE to allow parallel decision making over licencing and value.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).